Drugs Flashcards
1
Q
Procainamide
A
- Ia
- Blocks INa and partially blocks IKr, slowing the action potential upstroke and prolonging the action potential duration
- Termination of sustained ventricular tachycardia (not first line). Ventricular tachycardia after MI (rarely used for this).
- Drug-induced lupus, only during long term oral use (not available PO in USA). Fever. Agranulocytosis
2
Q
Quinidine
A
- Ia
- Blocks INa and partially blocks IKr, slowing the action potential upstroke and prolonging the action potential duration. Also binds the M2 muscarinic receptor for vagolytic effects
- Converts atrial fibrillation or flutter to sinus rhythm (rarely used for this). Maintain sinus rhythm in patients with atrial fibrillation (but can raise mortality)
- Cinchonism (CNS toxicity: tinnitus, hearing loss, delirium, and psychosis). Nausea, vomiting, diarrhea
3
Q
Disopyramide
A
- Ia
- Blocks INa and blocks IKr, slowing the action potential upstroke and prolonging the action potential duration. Also binds the M2 muscarinic receptor for vagolytic effects (stronger than quinidine)
- Hypertrophic obstructive cardiomyopathy (but not commonly used)
- Antimuscarinic side effects (urinary retention, constipation, blurred vision, dry mouth, closed-angle glaucoma)
4
Q
Lidocaine
A
- Ib
- Binds INa+ channel in active and inactive states, but not in the resting state. So it has little effect in normal tissue, but does exert effects in sick (ischemic) tissue.
- Ventricular arrhythmias, particular post-MI
- CNS toxicity: confusion, delirium, paresthesias, grand mal seizures
5
Q
Mexiletine
A
- Ib
- Binds INa+ channel in active and inactive states, but not in the resting state. So it has little effect in normal tissue, but does exert effects in sick (ischemic) tissue.
- Chronic suppression of ventricular arrhythmias (not first line, but sometimes)
- Nausea, vomiting
6
Q
Flecainide
A
- Ic
- Sodium channel blocker, prolongs conduction time. Has negative inotropic effects
- Acute conversion of atrial fibrillation to sinus rhythm. Maintenance of sinus rhythm in atrial fibrillation. Suppression of premature ventricular contractions (rarely used for this, raises mortality).
- Confusion, irritabilityIcSodium channel blocker, prolongs conduction time. Has negative inotropic effects
- Acute conversion of atrial fibrillation to sinus rhythm. Maintenance of sinus rhythm in atrial fibrillation. Suppression of premature ventricular contractions (rarely used for this, raises mortality).Confusion, irritability
7
Q
Propafenone
A
- Ic
- Sodium channel blocker, some β-blocking activity, negative inotropic effects
- Acute conversion of atrial fibrillation to sinus rhythm. Maintenance of sinus rhythm in atrial fibrillation. Suppression of premature ventricular contractions (rarely used for this, raises mortality).
- Can exacerbate bronchospasm (β-blocker…)
8
Q
Beta-blockers
A
- II
- Decrease slope of phase 4 in the SA node, and decrease the upstroke velocity in the SA and AV node, slowing conduction
- Slowing of ventricular response in atrial fibrillation. Disrupting reentrant arrhythmias. Suppressing premature ventricular contractions or atrial premature beats
- Bronchospasm, depression, cognitive impairment, hypotension
9
Q
Amiodarone
A
- III
- Blocks potassium channels, increases action potential duration and effective refractory period. Also blocks Na+ channels, β receptors, and Ca2+ channels (class I, II, and IV-like effects). Most effective, but has significant side effects.
- Suppression of ventricular tachycardia (defibrillators more effective). Maintenance of sinus rhythm in atrial fibrillation/flutter. Acute conversion from atrial fibrillation to sinus rhythm.
- Hyperthyroidism and hypothyroidism. Pulmonary fibrosis, liver toxicity, photodermatitis (grayish-blue skin discoloration). Dronedarone, a congener, has fewer side effects.
10
Q
Sotalol
A
- III
- Blocks K+ channels with some β-blocking activity
- Maintenance of sinus rhythm in atrial fibrillation/flutter. Prevention of AVNRT, AVRT. Ventricular tachyarrhythmias.
- Similar side effects to β-blockers: bronchospasm, depression, hypotension, cognitive impairment
11
Q
Dofetilide
A
- III
- Blocks K+ channels, and some Na+ channel blocking activity
- Maintenance of sinus rhythm in atrial fibrillation/flutter
- Headaches, GI complaints
12
Q
Ibutilide
A
- III
- K+ channel blocker
- Acute termination of atrial fibrillation and atrial flutter
- Few extracardiac effects other than GI complaints
13
Q
Verapamil
A
- IV
- Ca2+ channel blockers, block L-type channels and prolong conduction time and refractory periods in the AV node
- Heart rate control in atrial fibrillation/flutter. Can be used to terminate supraventricular tachycardias.
- Constipation and peripheral edema (from smooth muscle interference in gut and vasodilation, respectively), hypotension
14
Q
Adenosine
A
- Unclassified
- Interacts directly with A1 adenosine receptors in the heart, activating K+ channel, indirectly decreasing L-type Ca2+ channel activity and the funny current, If. Causes marked hyperpolarization and transient elective heart block.
- Diagnosis and termination of supraventricular tachycardias by producing transient heart block. Effective in terminating reentrant rhythms (acts as a reset button).
- Transient flushing, chest pressure, and chest burning
15
Q
Digoxin
A
- Unclassified
- Complicated mechanism: direct membrane effects (mediated by blocking Na+/K+ ATPase), and indirect effects (vagomimetic). Slows conduction, mainly in the SA node, atria, and AV node.
- Control of ventricular response in atrial fibrillation/flutter (usually with a β-blocker or Ca2+ channel blocker)
- Yellow vision, anorexia, nausea, vomiting, disorientation, hallucination. Toxicity treated with anti-digoxin antibody fragments
16
Q
Aspirin
A
- Platelet aggregation inhibitor
- Acetylates cyclooxygenase, irreversibly inhibiting it. Prevents production of ThromboxaneA2 (platelet activator)
- Function returns to normal after 7-10 days when new platelets appear in circulation.
17
Q
NSAIDs
A
- Platelet aggregation inhibitor
- Reversibly inhibits cyclooxygenase, function returns when drug concentration falls.
18
Q
Clopidogrel
A
- Platelet aggregation inhibitor
- P2Y12 ADP receptor blocking agent, can be used with aspirin. Needs to be activate, some people resistant.
- Trade name: Plavix
19
Q
Ticlopidine
A
- Platelet aggregation inhibitor
- ADP receptor blocking agent
- Trade name: Ticlid, use is associated with increased incidence of Thrombotic Thrombocytopenic Purpura (TTP) in 1:2000-4000 patients
20
Q
Prasugrel
A
- Platelet aggregation inhibitor
- ADP receptor blocking agent, used in patients resistant to clopidogrel
- Trade name: Efient
21
Q
Ticagrelor
A
- Platelet aggregation inhibitor
- ADP receptor blocking agent, used in patients resistant to clopidogrel
- Trade name: Brilinta
22
Q
Abciximab
A
- Platelet aggregation inhibitor
- Humanized murine Fab monoclonal antibody binds to and inhibits GP IIb/IIIa function
- Trade name: ReoPro
23
Q
Dipyridamole
A
- Platelet aggregation inhibitor
- Inhibits adenosine uptake, acts on PLA2, causes increased platelet cAMP, leading to inhibition
- Trade name: Persantine
24
Q
Warfarin
A
- Vitamin K Antagonist
- Inhibits vitamin K epoxide reductase (VKORC1)Anticoagulant
- Trade name: Coumadin
25
Q
Low Molecular Weight Heparin
A
- Heparin
- Enhanced inactivation of factor Xa relative to heparin
- Anticoagulant
- Reduced incidence of heparin induced thrombocytopenia, and reduced risk of osteoporosis. Can also be self-administered.
26
Q
Heparin
A
- Heparin
- Lower molecular weight inhibits Xa, higher molecular weight inhibits thrombin and binds platelets. All enhance antithrombin activity.
- Anticoagulant
- Can cause heparin induced thrombocytopenia, and osteoporosis (when used chronically), can be self administered.
27
Q
Fondaparinux
A
- Synthetic heparin analog
- Enhances ability of antithrombin to inhibit factor Xa, but no anti-thrombin activity.
- Anticoagulant
- Trade name: Arixtra. No thrombocytopenia, but cannot be used in patients in renal failure.
28
Q
Rivaroxaban
A
- Direct Factor Xa Inhibitor
- Small molecule inhibitor of factor Xa (free and bound)
- Anticoagulant
- Trade name: Xarelto, monitoring not required
29
Q
Apixiban
A
- Direct Factor Xa Inhibitor
- Small molecule inhibitor of factor Xa (free and bound)
- Anticoagulant
- Trade name: Eliquis, monitoring not required
30
Q
Hirudin
A
- Direct Thrombin Inhibitor
- Binds both the active pocket site and fibrinogen binding exosite on thrombin.
- Anticoagulant
- Originally derived from leeches, now made with recombinant DNA technology
31
Q
Bivalirudin
A
- Direct Thrombin Inhibitor
- Binds both the active pocket site and fibrinogen binding exosite on thrombin, but is a truncated version of hirudin
- Anticoagulant
- Need to test activated clotting time at 45 minutes, avoid in renal failure
32
Q
Argatroban
A
- Direct Thrombin Inhibitor
- Binds only the active site pocket on thrombin
- Anticoagulant
- Need to test APTT at 2 hours, avoid in liver failure
33
Q
Dabigatran
A
- Direct Thrombin Inhibitor
- Binds only the active site pocket on thrombin
- Anticoagulant
- Dabigatran etexilate (trade name: Pradaxa) is a prodrug that is converted to dabigatran in the gut, does not need to be monitored
34
Q
Lepirudin
A
- Direct Thrombin Inhibitor
- Binds only the active site pocket on thrombin
- Anticoagulant
- Need to test APTT at 2 hours, avoid in renal failure
35
Q
Atorvastatin
A
- Statin
- Inhibits HMG CoA Reductase, decreasing cholesterol synthesis. Leads to increased LDL receptors
- High intensity (40/80 mg/day), moderate intensity (10 mg/day)CYP3A4
36
Q
Rosuvastatin
A
- Statin
- Inhibits HMG CoA Reductase, decreasing cholesterol synthesis. Leads to increased LDL receptors
- High intensity (20/40 mg/day), moderate intensity (5/10 mg/day)
- Minimally metabolized by CYP2C9